Technical testing and analysis
TFS TRIAL FORM SUPPORT AS
Revenue 2025
NOK 682,000
Operating profit
NOK −85,000
Equity
NOK 4.2m
Incorporated
2008
Share capital
NOK 110,000
Roles
Regnskapsfører
Regnskapsfører
Styrets lederJesper Hjort
StyremedlemPatrik Mikael Polo Darsund
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| TFS INTERNATIONAL CLINICAL DEVELOPM | 100.0% | 1000.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.